Cyclophosophamide therapy for lupus nephritis: Poor renal survival in Arab children

Pediatric Nephrology

Volumn 18, Issue 4, 2003, Pages 357-361

  Al Salloum, Abdullah A ^a  

^a KING KHALID UNIVERSITY HOSPITAL   (Saudi Arabia)

Author keywords

Cyclophosphamide; Hypertension; Lupus nephritis; Renal failure

Indexed keywords

ANTIEMETIC AGENT; ANTIHYPERTENSIVE AGENT; CREATININE; CYCLOPHOSPHAMIDE; MESNA; METHYLPREDNISOLONE; PREDNISONE; ALKYLATING AGENT;

ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG PULSE THERAPY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HAIR LOSS; HEMORRHAGIC CYSTITIS; HUMAN; INFECTION; KIDNEY FUNCTION; LONG TERM CARE; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; NAUSEA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RENOVASCULAR HYPERTENSION; SAUDI ARABIA; SCHOOL CHILD; SURVIVAL RATE; ARAB; BIOLOGICAL PHENOMENA AND FUNCTIONS CONCERNING ORGAN SYSTEMS; CHILD; CLINICAL TRIAL; DRUG EFFECT; FOLLOW UP; KIDNEY; KIDNEY FUNCTION TEST; LEUKOCYTE COUNT; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; PATHOLOGY; TREATMENT OUTCOME;

ALKYLATING AGENTS; ARABS; CHILD; CYCLOPHOSPHAMIDE; FEMALE; FOLLOW-UP STUDIES; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; HUMANS; KIDNEY; KIDNEY FUNCTION TESTS; LEUKOCYTE COUNT; LUPUS NEPHRITIS; MALE; PROSPECTIVE STUDIES; TISSUE SURVIVAL; TREATMENT OUTCOME;

EID: 0038159556     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-003-1110-8     Document Type: Article

References (33)

1. McCurdy DK, Lehman TJ, Bernstein B, Hanson V, King KK, Nadorra R, Landing BH (1992) Lupus nephritis: prognostic factors in children. Pediatrics 89:240-246
2. Bono L, Cameron JS, Hicks JA (1999) The very long-term prognosis and complications of lupus nephritis and its treatment. QJ Med 92:211-218
3. Cameron JS (1994) Lupus nephritis in childhood and adolescence. Pediatr Nephrol 8:230-249
4. Emre S, Bilage I, Sirin A, Kilicaslan I, Nayir A, Okteon F, Uysal V (2001) Lupus nephritis in children: prognostic significance of clinicopathological findings. Nephron 87:118-126
5. Valeri A, Radhakrishnan J, Estes D, Agati VD, Kopelman R, Pernis A, Flis R, Piranic C, Appel GB (1994) Intravenous pulse cyclophosphamide treatment of severe lupus nephritis: a prospective five-year study. Clin Nephrol 42:71-78
6. Tejani A, Nicastri AD, Cuen CK, Fikrig S, Gurumurthy K (1983) Lupus nephritis in black and hispanic children. Am J Dis Child 137:481-483
7. Austin HA, Klippel JH, Balow JE, Le Ricue NE, Steinberg AD, Plotz PH, Decker J (1986) Therapy of lupus nephritis, controlled trial of prednisone and cytotoxic drugs. N Engl J Med 314:614-619
8. Steinberg AD, Steinberg SC (1991) Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum 34:945-950
9. Boumpas DT, Austin HA, Vaughn EM, Klippal J, Steinberg AD, Yarboro CH, Balow JE (1992) Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 340:741-745
10. Donadio JV, Glussock RJ (1993) Immuno-suppressive drug therapy in lupus nephritis. Am J Kidney Dis 21:239-250
11. Cameron SJ (1989) The treatment of lupus nephritis. Pediatr Nephrol 3:350-362
12. Lehman TJ, Onel K (2000) Intermittent intravenous cyclophosphamide arrests progression of the renal chronicity index in childhood systemic lupus erythematosus. J Pediatr 136: 243-247
13. Mok CC, Ho CT, Siu YP, Chan KW, Kwan TH, Ian CS, Wong RW, Au TC (2001) Treatment of diffuse proliferative lupus glomerulonephritis: a comparison of two cyclophosphamide containing regimens. Am J Kidney Dis 38:256-264
14. Lehman TJ, Sherry DD, Wagner Weiner L, Mc Curdy DK, Emery HM, Magilary DB, Kovalesky A. (1989) Intermittent intravenous cyclophosphamide therapy for lupus nephritis. J Pediatr 114:1055-1060
15. Pablos JL, Millet VG, Reino JJ (1994) Remission of lupus nephritis with cyclophosphamide and late relapses following therapy withdrawal. Scand J Rheumatol 23:142-144
16. Niaudet P (2000) Treatment of lupus nephritis in children. Pediatr Nephrol 14:158-166
17. Barron KS, Person DA, Brewer EJ, Beale MG, Robson AM (1982) Pulse methylprednisolone therapy in diffuse proliferative lupus nephritis. J Pediatr 101:137-141
18. Kimberly RP, Lockshin MD, Sherman RL, Mc Dougal JS, Luman RD, Christian CL (1981). High dose intravenous methyl prednisolone pulse therapy in systemic lupus erythematosus. Am J Med 70:817-824
19. Tanaka H, Tateyama T, Waga S (2001) Methyl prednisolone pulse therapy in Japanese children with severe lupus nephritis. Pediatr Nephrol 16:817-819
20. Dooley MA, Hogan S, Jennette C, Falk R (1997) Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Kidney Int 51:1188-1195
21. Hopkinson ND, Jenkinson C, Muir KR, Doherty M, Powell RJ (2000) Racial group, socioeconomic status, and the development of persistent proteinuria in systemic lupus erythematosus. Ann Rheum Dis 59:116-119
22. Austin HA, Balow J (1999) Natural history and treatment of lupus nephritis. Semin Nephrol 19:2-11
23. Al Attia HM, Al Ahmed YH, Chandani AV (1998) Serological markers in Arabs with lupus nephritis. Lupus 7:198-201
24. Garcia CO, Molina JF, Urena SG, Scopelitis E, Wilson WA, Gharavi AE, Espinoza LR (1996) Autoantibody profile in African American patients with lupus nephritis. Lupus 5:602-605
25. Naiker IP, Chrystal V, Randeree IG, Seedat YK (1997) The significance of arterial hypertension at the onset of clinical lupus nephritis. Postgrad Med J 73:230-233
26. Donadio JV, Hart GM, Berozstralh EJ, Holley KE (1995) Prognostic determinants in lupus nephritis: a long-term clinicopathologic study. Lupus 4:109-115
27. Lim CS, Chin HJ, Jung YC, Kim YS, Ann C, Han JS, Kim S, Lee JS (1999) Prognostic factors of diffuse proliferative lupus nephritis. Clin Nephrol 52:139-147
28. Colon PJ, Fischer CA, Levesque MC, Smith SR, Clair EW, Allen NB, Fleming JA, Howell DN (1996) Clinical, biochemical and pathological predictors of poor response to intravenous cyclophosphamide in patients with proliferative lupus nephritis. Clin Nephrol 46:170-175
29. Esdaile JM, Joseph L, Mackenzie T, Kashgarium M, Hayslett JP (1994) The benefit of early treatment with immuno-suppressive agents in lupus nephritis. J Rheumatol 21:2046-2051
30. Jakopsen S, Starklint H, Petersen J, Ullman S, Junker P, Voss A, Rasmussen JM, Tarp V, Poulsen LH, Hansen GVO, Skaarup B, Hansen TM, Podenphant J, Halberg P (1999) Prognostic value of renal biopsy and clinical variables in patients with lupus nephritis and normal serum creatinine. Scand J Rheumatol 28:288-299
31. Boumpas DT, Austin HA, Vaughan EM, Yarboro CH, Klippel JH, Balow JE (1993) Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 119: 366-369
32. Belmont HM, Storch M, Buyon J, Abramson S (1995) New York University/Hospital for joint diseases experience with intravenous cyclophosphamide treatment: efficacy in steroid unresponsive lupus nephritis. Lupus 4:104-108
33. Pryor BD, Bologua SG, Kalil LE (1996) Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus. Arthritis Rheum 39:1475-1482